Shanghai Pharmaceuticals (HKG:2607, SHA:601607) posted 1.08 billion yuan in attributable net profit for the third quarter, up 57% from a year ago.
EPS moved to 0.29 yuan, an increase of 53% year over year, a Thursday filing with the Hong Kong Exchange showed.
For the three months ended Sept. 30, operating revenue was 75.49 billion yuan, up 3% from a year earlier, the pharmaceutical and healthcare giant said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments